

19 September 2018

Dear Shareholder,

NON-RENOUCEABLE RIGHTS ISSUE TO RAISE UP TO \$735,721

Earlier today, Impression Healthcare Limited (**Company**) announced that it would be offering shareholders the opportunity to participate in a non-renounceable pro-rata entitlement offer to raise up to \$735,721 (before costs) (**Offer**), on the basis of one fully paid ordinary share in the capital of the Company (**New Share**) for every four fully paid ordinary shares held at the record date, at an issue price of \$0.01 per New Share.

If the Offer is fully subscribed, a total of 73,572,062 will be issued (subject to rounding).

Only shareholders with a registered address in Australia will be eligible to participate in the Offer (**Eligible Shareholders**).

The Offer is made to Eligible Shareholders registered at 7.00pm (Melbourne-time) on the record date of 26 September 2018 (**Record Date**).

The Offer will be made pursuant to a prospectus to be lodged with ASIC and ASX on 19 September 2018 (**Prospectus**) and which will be available on the Company's website at www.impression.healthcare and on the ASX website at www.asx.com.au.

Indicative Timetable

The timetable for the Offer is as follows:

Event	Date
Announcement of Offer to market (ASX)	19 September 2018
Notice of Offer sent to Shareholders and Optionholders	19 September 2018
Lodgment of Prospectus with ASIC and ASX	19 September 2018
Ex-Date	25 September 2018
Record Date	26 September 2018
Prospectus and entitlement and acceptance form dispatched to shareholders	01 October 2018
Opening date	01 October 2018
Closing date	17 October 2018
New Shares quoted on a deferred settlement basis	19 October 2018
Notification of shortfall	19 October 2018
Issue date. Allotment and issue of New Shares	22 October 2018

Purpose of Offer

Successful completion of the Offer will raise up to \$735,721 (before costs). Funds raised from the Offer will be used to support the growth of the new medicinal cannabis division of the Company, including to support the collaboration agreement with AXIM Biotechnologies Incorporated; to continue cost-effective growth of the oral health-care device business; to redeem a proportion of the Company's existing convertible notes; and for general working capital of the Company.

Shortfall

If Eligible Shareholders do not wish to take up any part of their entitlement they are not required to take any action. That part of their entitlement that is not taken up, and which is not subscribed for under a shortfall offer by other Eligible Shareholders, will form the shortfall and will be placed, subject to a first right of refusal by the lead manager, at the discretion of the Company board within 3 months of the Closing Date of the Offer.

Prospectus

Details of the Offer will be contained in the Prospectus. Eligible Shareholders should consider the Prospectus carefully before deciding whether to participate in the Offer and consult with their professional advisors if they have any queries.

The Company's Directors intend to apply for their entitlement under the Entitlement Offer.

Yours sincerely



Troy Valentine

Non- Executive Chairman